KR850005843A - 치환된 헥사히드로 아릴퀴놀리진의 제조방법 - Google Patents

치환된 헥사히드로 아릴퀴놀리진의 제조방법 Download PDF

Info

Publication number
KR850005843A
KR850005843A KR1019850000635A KR850000635A KR850005843A KR 850005843 A KR850005843 A KR 850005843A KR 1019850000635 A KR1019850000635 A KR 1019850000635A KR 850000635 A KR850000635 A KR 850000635A KR 850005843 A KR850005843 A KR 850005843A
Authority
KR
South Korea
Prior art keywords
compound
formula
alkyl
hydrogen
benzo
Prior art date
Application number
KR1019850000635A
Other languages
English (en)
Other versions
KR900003651B1 (ko
Inventor
알. 후프 조엘
Original Assignee
제임스 에프. 노톤
머크 앤트캄파니 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 제임스 에프. 노톤, 머크 앤트캄파니 인코포레이티드 filed Critical 제임스 에프. 노톤
Publication of KR850005843A publication Critical patent/KR850005843A/ko
Application granted granted Critical
Publication of KR900003651B1 publication Critical patent/KR900003651B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/81—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

내용 없음

Description

치환된 헥사히드로 아릴퀴놀리진의 제조방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (6)

  1. 하기 구조식 (Ⅱa)의 화합물을, 약 0℃ 내지 불활성 용매의 환류 온도에서 약 0.5내지 48시간동안 산 수용체의 존재하에 불활성 용매중에서 일반식 R4-X-할로의 아실화제로 처리시킴을 특징으로 하여 하기 일반식(Ⅰ)의 화합물을 제조하는 방법.
    상기식에서, Ar은 R1,R2벤조-[b] 푸로, R1,R2벤조-[b] 티에노-, 티에노-및 푸로-등으로부터 선택된 방향족 헤테로사이클을 나타내며;
    R1및 R2는 각각, 1) 수소, 2) 할로, 3) 히드록시, 4)C1-3알콕시, 또는, 5) C1-6알킬이며;
    R3는 1) 수소, 2)(여기서 R은 수소 또는 C1-3알킬이다), 3) 치환되지 않거나 또는 하나 이상의 하기의 것을 치환된 C1-6알킬이며; a) 히드록시, b) 카르복시, c) C1-3알콕시카르보닐, d) 할로, e) C1-3알콕시, f) -CONR6R7[여기서 R6및 R7은 동일하거나 다르며 수소 또는 C1-5알킬이거나 또는 함께 직접 결합하여 5내지 7의 환상(memberedring)을 형성하거나 또는 O,N, 및 S로 부터 선택된 헤테로원자를 통해 함께 결합되어, 부착되는 질소원자와 6-원 헤테로 사이클을 형성한다]또는 g) -NR6R7
    R4는 1) -OR8(여기서 R8은 수소 또는 치환되지 않거나 또는 하나이상의 a) OR, 또는 b) -NRCOR로 치환된 C1-6알킬이다), 2) -N(R8)2, 3) -CO2R8, 4) -CONR6R7, 5) 치환되지 않거나 또는 a) OR8b) 할로, c) CO2R8, d) CONR6R7등으로 치환된 C1-6알킬, 6) C2-5알켄일, 7) C2-5알킨일, 8) C3-6사이클로알킬, 9) N,O 및 S로 부터 선택된 헤테로원자 2개까지를 갖는 5 또는 6원 헤테로사이클 10) 치환되지 않거나 하나 이상의 a) 할로, 또는 b) OR로 치환되 탄소수 6내지 10의 카르보사이클 아릴이거나, 또는 R5는 1) 수소, 2) 치환되지 않거나 또는 하나 이상의 a) OR8b) -NR8COR8또는 c) CO2R8등으로 치환된 C1-6알킬 3) -CO2R8또는 4) -CONR6R7이며;
    R3및 R4는 직접 또는 O,N 및 S로부터 선택된 헤테로원자를 통해 함께 결합하여 부착되는 질소원자와 5 또는 6-원 헤테로사이클을 형성한다.
  2. 제1항에 있어서, Ar은 R1,R2-벤조[b] 푸로 또는 R1,R2-벤조[b] 티에노-이고; R1및 R2는 수소 또는 할로이며; R3는 C1-6알킬이고; X는 -SO2-이며, R4는 C1-6알킬, 디(C1-3알킬) 아미노, 할로-C1-6알킬, 히드록시-C1-6알킬, C2-5알켄일, C6-10카르보실 아릴, 5 또는 6-원 헤테로사이클, -CO2R8, C1-6알킬-CO2R8, 또는-C1-6알킬 -CONR6R7이며; R5는 수소 또는 C1-6알킬인 방법.
  3. 제2항에 있어서, R1및 R2는 수소이고, R3는 메틸이고, R4는 C1-6알킬, 히드록시-C1-6알킬, 디(C1-3알킬)아미노, 2-푸르푸릴, 또는 C1-3알콕시카르보닐 에틸이며 R5는 수소인 방법.
  4. 제3항에 있어서, Ar은 벤조[b] 푸로-이고 R3는 -CH3이고, X는 -SO2-이며 R4는 -CH2CH3, -N(CH3)2, -CH2CH2OR 또는 -CH2CH2CH2OR(여기서 R은 수소 또는 메틸이다)인 화합물을 제조하는 방법.
  5. 제1항에 있어서, N-(1,3,4,6,712ba-헥사히드로-2H-벤조[b] 푸로[2,3a]-퀴놀리진-2β-일)-N-메틸-2-히드록시에탄술폰 아미드; N-(1,3,4,6,7,12ba-헥사히드로-2H-벤조[b] 푸로[2,3a]-퀴놀리진-2β-일)-N-메틸-3-히드록시프로판술폰아미드; N-(1,3,4,6,7,12ba-헥사히드로-2H-벤조[b] 푸로[2,3a]-퀴놀리진-2β-일)-N-메틸-3-메탄술폰아미드; (+)-N-(1,3,4,6,7,12ba-헥사히드로-2H-벤조[b] 푸로-[2,3a]-퀴놀리진-2β-일)-N,N',N'-트리메틸술퍼아미드; N-(1,3,4,6,7,12ba-헥사히드로-2H-벤조[b]-티에닐-[2,3a]-퀴놀리진-2β-일)-N-메틸-메탄술폰아미드; 또는 이의 약리학적으로 허용되는 염을 제조하는 방법.
  6. 하기 구조식(1)의 화합물을 일반식 HOCH2CH-X-할로(여기서 X는 -CO-, -CS- 또는 SO2-이고 할로는 클로로, 브로모 또는 요오드이다)의 아실화제로 처리시키거나;
    하기 일반식(2)의 화합물을 ⅰ) R9이 -COR10, -CO2OH4Ar, 또는 -CO2R10일 때 알칼리 또는 산; ⅱ) R9이 -Si(R11)3일때 산; 또는 ⅲ) R9이 -CO2CH2Ar일때 가수소분해로 탈보호시키거나;
    하기 구조식(3)의 화합물을 SO2로 처리하고 이어서 산화에틸렌으로 처리하거나; 하기 일반식(4)의 화합물을 R9가 H 또는 -CO2CH2Ar일때 촉매적으로 수소화시키거나; 하기구조식(5)의 화합물을 환원시키거나; 하기 구조식(6)의 화합물을 환원시키거나;하기 구조식(7)의 화합물을 각각 강염기 또는 활성금속으로 처리하고 이어서 포름알데히드로 처리하거나; 하기 구조식(8)의 화합물을 환원시키거나; 하기 구조식(9)의 화합물을 환원시키거나; 하기 구조식(10)의 화합물을 환원시키거나; 하기 구조식(11)의 화합물을 환원시키거나; 하기 구조식(12)의 화합물을 환원시키거나; 하기 구조식(13)의 화합물을 환원시키거나; 하기구조식(14)의 화합물을 환원시키거나; 하기 구조식(15)의 화합물을 환원시키거나; 하기 일반식(16)의 화합물을 가열시키거나; 하기 구조식(17)의 화합물을로 처리하거나; 하기 구조식(18)의 화합물을 PPA, POCl3또는 HCl로 처리하거나; 하기 구조식(19)의 화합물을 산 촉매전위 반응시킴을 특징으로 하여 하기 구조식(I')의 화합물을 제조하는 방법.
    상기식(2)에서 R9은 -COR10, -CO2CH2Ar, -CO2R10또는 -Si(R11)3이며, 상기식(7)에서 R12는 수소 또는 할로이다.
    　※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019850000635A 1984-02-02 1985-02-01 치환된 헥사히드로 아릴퀴놀리진 및 이의 제조방법 KR900003651B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57623384A 1984-02-02 1984-02-02
US576,233 1984-02-02
US576233 1995-12-21

Publications (2)

Publication Number Publication Date
KR850005843A true KR850005843A (ko) 1985-09-26
KR900003651B1 KR900003651B1 (ko) 1990-05-28

Family

ID=24303506

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019850000635A KR900003651B1 (ko) 1984-02-02 1985-02-01 치환된 헥사히드로 아릴퀴놀리진 및 이의 제조방법

Country Status (15)

Country Link
EP (1) EP0154142B1 (ko)
JP (1) JPS60188385A (ko)
KR (1) KR900003651B1 (ko)
AT (1) ATE44529T1 (ko)
AU (1) AU576550B2 (ko)
CA (1) CA1240677A (ko)
DE (1) DE3571438D1 (ko)
DK (1) DK45385A (ko)
ES (1) ES8609323A1 (ko)
GR (1) GR850211B (ko)
IE (1) IE850253L (ko)
IL (1) IL74147A (ko)
NZ (1) NZ210982A (ko)
PT (1) PT79871B (ko)
ZA (1) ZA85789B (ko)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4690928A (en) * 1984-02-02 1987-09-01 Merck & Co., Inc. Substituted hexahydro arylquinolizines as α2 blockers
GB8420602D0 (en) * 1984-08-14 1984-09-19 Wyeth John & Brother Ltd Thienoquinolizines
DK127086A (da) * 1985-03-25 1986-09-26 Schering Corp Substituerede 1,8-naphthyridoner, fremgangsmaader til deres fremstilling og farmaceutiske kompositioner, der indeholder disse forbindelser
AU582663B2 (en) * 1985-08-10 1989-04-06 John Wyeth & Brother Limited Sulphonamides
US4686226A (en) * 1985-09-03 1987-08-11 Merck & Co., Inc. Substituted benzo[b]furo- and benzo[b]thieno quinolizines
US4835276A (en) * 1986-07-03 1989-05-30 Merck & Co., Inc. Preparation of n-formamidoyl[(s)-1-t-butoxy-3-methyl-2-amino)]1,2,3,4 tetrahydrobenzo [b]furo [2,3-c]pyridine and derivatives
US4814452A (en) * 1986-07-03 1989-03-21 Merck & Co., Inc. Enantioselective synthesis of 1,3,4,6,7,12b(S)-hexahydro-2H-benzo[b]furo[2,3-a]quinolizin-2-one
NZ221485A (en) * 1986-08-28 1991-04-26 Merck & Co Inc Hexahydroarylquinolizine derivatives and pharmaceutical compositions
US4831035A (en) * 1986-08-28 1989-05-16 Merck & Co., Inc. Substituted hexahydroarylquinolizines
US4956365A (en) * 1987-04-13 1990-09-11 Syntex (U.S.A.) Inc. Decahydro-8H-isoquino(2,1-g)(1,6)naphthyridine derivatives and related compounds
CA1321751C (en) * 1989-02-21 1993-08-31 Eugene C. Crichlow Mechanism mediating ruminal stasis in ruminal lactic acidosis
WO2011067145A1 (en) 2009-12-04 2011-06-09 Nerviano Medical Sciences S.R.L. Tricyclopyrazole derivatives
GB201509006D0 (en) 2015-05-26 2015-07-08 Redx Pharma Plc Antibacterial compounds

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1470065C3 (de) * 1961-06-19 1980-07-17 Merck Patent Gmbh, 6100 Darmstadt Verfahren zur Herstellung von Chinolizinderivaten
GB1435573A (en) * 1973-05-25 1976-05-12 Wyeth John & Brother Ltd Indoloquinolizines
US4181657A (en) * 1978-07-14 1980-01-01 Miles Laboratories, Inc. 2-Aminooctahydroindolo[2,3-a]quinolizines useful in treating cardiovascular disorders
GB2106909B (en) * 1981-10-07 1984-09-19 Wyeth John & Brother Ltd Benzoquinolizines

Also Published As

Publication number Publication date
IL74147A (en) 1988-08-31
NZ210982A (en) 1988-04-29
GR850211B (ko) 1985-05-24
EP0154142A1 (en) 1985-09-11
ATE44529T1 (de) 1989-07-15
IL74147A0 (en) 1985-04-30
KR900003651B1 (ko) 1990-05-28
ZA85789B (en) 1986-09-24
CA1240677A (en) 1988-08-16
ES8609323A1 (es) 1986-07-16
ES539799A0 (es) 1986-07-16
AU3822085A (en) 1985-08-08
DE3571438D1 (en) 1989-08-17
PT79871A (en) 1985-02-01
DK45385D0 (da) 1985-02-01
EP0154142B1 (en) 1989-07-12
AU576550B2 (en) 1988-09-01
IE850253L (en) 1985-08-02
JPS60188385A (ja) 1985-09-25
DK45385A (da) 1985-09-18
PT79871B (en) 1986-12-15

Similar Documents

Publication Publication Date Title
KR850005843A (ko) 치환된 헥사히드로 아릴퀴놀리진의 제조방법
CA2340999A1 (en) 5-arylindole derivatives
NO165145C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 1h-imidazo-(4,5-c)-kinolin-4-aminderivater.
KR940014396A (ko) 이미다조피리딘
ES2082780T3 (es) Derivados de acido bisfosfonico heterociclicos.
CA2036618A1 (en) Fused thiophene derivatives, their production and use
NO882608D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive pyrazolopyrideirer.
MY119623A (en) Quinoline and quinazoline compounds useful in therapy, particularly in the treatment of benign prostatic hyperplasia
IE38886B1 (en) Heterocyclic compounds
BG94282A (bg) 2,9-дизаместени-4н-пиридо/1,2,-а/пиримидин-4-они
NO177007C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive tetrahydrobenzimidazolderivater
NO871861L (no) Fremgangsmaate for fremstilling av nye dopamin beta-hydroxylase inhibitorer.
GB1410511A (en) Thiazole cardiovascular agnets
ES8800142A1 (es) Un procedimiento para preparar un derivado de semicarbazida
ES8802524A1 (es) Un procedimiento para la preparacion de derivados de beta-lactama.
KR960701029A (ko) 하이드록시메틸 푸라잔 카복실산 유도체 및 심장 혈관 질환 치료에서의 이의 용도(Hydroxymethyl furazane carboxylic acid derivatives and their use in the treatment of cardio-vascular conditions)
NO159854C (no) Analogifremgangsm te til fremstilling av terapeutisk aktive beta-karbolin-3-karboksylsyrederivater.
PT85378A (en) Process for the preparation of new tetracyclic indole derivatives and of pharmaceutical compositions containing the same
ES2042727T3 (es) Acidos 1,3,4,9-tetrahidropirano(3,4-b)indol-1-acetico.
IE45889L (en) 4-AMINO-BENZO (b) BICYCLO [3.3.1] NONENE DERIVATIVES,¹ANTI-DEPRESSANTS
EP0461264A4 (en) Ethynylphenyl derivative, production thereof, and remedy for diseases of circulatory organs containing the same as active ingredient
MX23618A (es) Compuesto heterociclicos de nitrogeno,hidrogenadosy procedimiento para su preparacion.
MX9709873A (es) Nueva forma cristalina del acido 7([1(alfa),5(alfa),6(alfa)]-6-amino-3-azabiciclo[3.1.0]hex-3 -il)-6-fluor-1-(2,4-difluorofenil)1,4-dihidro-4-oxo-1,8-naft iridin-3-carboxilico anihdro, sal del acido metano-sulfonico, composiciones que la contienen, y
HUT58721A (en) Process for producing indolyl derivatives and pharmaceutical compositions containing them as active components
FI943730A (fi) Menetelmä angiotensiini-II-antagonistina aktiivisen 3-(2'-N-bentsoyylisulfonamido-bifen-4-yyli)metyyli-5,7-dimetyyli-2-etyyli-3H-imidatso/4,5-b/pyridiinin valmistamiseksi

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
NORF Unpaid initial registration fee